New PET scan could reveal which breast cancer patients respond to immunotherapy

NCT ID NCT07705438

Recruiting now Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests whether a special PET scan that tracks Granzyme B—a molecule released by active immune cells—can predict how well immunotherapy works in people with advanced triple-negative breast cancer. Thirty participants will receive the scan before and after two cycles of immunotherapy. The goal is to see if changes in Granzyme B levels on the scan can serve as an early marker of treatment response, potentially guiding personalized therapy decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Granzyme B PET/CT scan using [68Ga]Ga-DOTA-GSI
What this could lead to: If successful, this imaging method could help doctors predict which patients will benefit from immunotherapy, avoiding ineffective treatments and side effects.
What could go wrong: This is a small, early-stage study (30 people) focused on imaging, not treatment. The scan may not reliably predict outcomes in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRANZYME B PET/CT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRANZYME B PET/CT IMMUNE CHECKPOINT INHIBITOR TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fudan Cancer Hospital
RECRUITING

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.